 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Afobazole |
| Other names | Obenoxazine |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 43.64%, pronouncedfirst-pass effect |
| Metabolism | extensive hepatic |
| Onset of action | 0.85±0.13 hours |
| Eliminationhalf-life | 0.82±0.54 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H21N3O2S |
| Molar mass | 307.41 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Fabomotizole (INN;[1] brand nameAfobazole) is ananxiolyticdrug launched in Russia in the early 2000s. It producesanxiolytic andneuroprotective effects without anysedative ormuscle relaxant actions.[citation needed] Itsmechanism of action remains poorly defined however, withGABAergic,NGF- andBDNF-release-promoting,MT1receptor agonism,MT3receptor antagonism, andsigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement withserotonin receptors.[2][3][4][5][6] Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.[7]
Experiments in mice have shown antimutagenic and antiteratogenic properties.[8]
Experiments in rats have shown beneficial effect in the model of ischemic stroke.[9]
Fabomotizole has found little clinical use outside Russia and has not been evaluated by the FDA.
